Morphine extended release - Assertio Therapeutics
Alternative Names: ARYMO; ARYMO ER; EG-P113; EG-PO66 Morphine; Egalet Morphine; Egalet-001; Morphine sulfate - Assertio TherapeuticsLatest Information Update: 31 Dec 2021
At a glance
- Originator Egalet
- Developer Zyla Life Sciences
- Class Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Pain
Most Recent Events
- 28 Sep 2018 Discontinued - Phase-II for Pain in Lithuania (PO), due to unfavourable cost-revenue margins and payor pressure in the extended release morphine space
- 28 Sep 2018 Discontinued - Phase-II for Pain in Poland (PO), due to unfavourable cost-revenue margins and payor pressure in the extended release morphine space
- 28 Sep 2018 Withdrawn for Pain in USA (PO), due to unfavourable cost-revenue margins and payor pressure in the extended release morphine space